<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208831</url>
  </required_header>
  <id_info>
    <org_study_id>CLDE225X1101</org_study_id>
    <nct_id>NCT01208831</nct_id>
  </id_info>
  <brief_title>An East Asian Study of LDE225</brief_title>
  <official_title>An East Asian Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase
      II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e.,
      Japanese and Chinese/Taiwanese) with advanced solid tumors that have progressed despite
      standard therapy or for which no standard therapy exists.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine maximum tolerated dose of single agent LDE225</measure>
    <time_frame>28 day cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>characterize safety and tolerability</measure>
    <time_frame>28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>characterize pharmacokinetics (PK) of single and repeated doses of LDE225</measure>
    <time_frame>28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess preliminary anti-tumor activity</measure>
    <time_frame>28 day cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Advanced Solid Tumor Cancers</condition>
  <condition>Medulloblastoma</condition>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>LDE225</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDE225</intervention_name>
    <arm_group_label>LDE225</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed diagnosis of advanced solid tumor (including medulloblastoma and basal cell
             carcinoma)

          -  blood work criteria

        Exclusion Criteria:

          -  patients with history of brain tumor (except recurrent medulloblastoma) or brain
             metastases

          -  positive HIV, hepatitis B or C

          -  impaired intestinal function

          -  impaired heart function

          -  pregnant or breast-feeding women

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-city</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced tumors</keyword>
  <keyword>hedgehog</keyword>
  <keyword>smoothened inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

